Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker.

ABSTRACT: This study investigated the anti-leukemic potential of BET inhibitors in combination with mTOR inhibitors, focusing on both BET-resistant and BET-sensitive AML cell lines. Our findings reveal a significant suppression of proliferation and induction of apoptosis across all tested cell lines following combined treatment. Interestingly, JQ1 (a specific BET inhibitor) triggered cell cycle arrest only in sensitive cells when used alone while addition of mTOR inhibitors extended this antiproliferative effect to BET-resistant cells as well. This observation underscores the potential of this combination therapy to circumvent existing resistance mechanisms. This study further confirmed an additive antitumor effect of the combined inhibitors in primary AML patient cells. We also identified EGR1 as a

SUBMITTER: Latancia MT 

PROVIDER: S-EPMC12627814 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature